Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes


Autoria(s): Dias-Junior, Carlos A.; Neto-Neves, Evandro M.; Montenegro, Marcelo F.; Tanus-Santos, Jose E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

04/10/2013

04/10/2013

2012

Resumo

The acute obstruction of pulmonary vessels by venous thrombi is a critical condition named acute pulmonary embolism (APE). During massive APE, severe pulmonary hypertension may lead to death secondary to right heart failure and circulatory shock. APE-induced pulmonary hypertension is aggravated by active pulmonary vasoconstriction. While blocking the effects of some vasoconstrictors exerts beneficial effects, no previous study has examined whether angiotensin II receptor blockers protect against the hemodynamic changes associated with APE. We examined the effects exerted by losartan on APE-induced hemodynamic changes. Hemodynamic evaluations were performed in non-embolized lambs treated with saline (n = 4) and in lambs that were embolized with silicon microspheres and treated with losartan (30 mg/kg followed by 1 mg/kg/h, n = 5) or saline (n = 7) infusions. The plasma and lung angiotensin-converting enzyme (ACE) activity were assessed using a fluorometric method. APE increased mean pulmonary arterial pressure (MPAP) and pulmonary vascular resistance index (PVRI) by 21 +/- 2 mmHg and 375 +/- 20 dyn s cm(-5) m(-2), respectively (P < 0.05). Losartan decreased MPAP significantly (by approximately 15%), without significant changes in PVRI and tended to decrease cardiac index (P > 0.05). Lung and plasma ACE activity were similar in both embolized and non-embolized animals. Our findings show evidence of lack of activation of the renin-angiotensin system during APE. The lack of significant effects of losartan on the pulmonary vascular resistance suggests that losartan does not protect against the hemodynamic changes found during APE.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Dsenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Dsenvolvimento Cientifico e Tecnologico (CNPq)

Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Identificador

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, NEW YORK, v. 385, n. 2, pp. 211-217, FEB, 2012

0028-1298

http://www.producao.usp.br/handle/BDPI/34042

10.1007/s00210-011-0695-x

http://dx.doi.org/10.1007/s00210-011-0695-x

Idioma(s)

eng

Publicador

SPRINGER

NEW YORK

Relação

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Direitos

closedAccess

Copyright SPRINGER

Palavras-Chave #ACUTE PULMONARY EMBOLISM #ANGIOTENSIN #LOSARTAN #PULMONARY HYPERTENSION #ANGIOTENSIN-CONVERTING ENZYME #ENDOTHELIN-RECEPTOR ANTAGONISM #INDUCED OXIDATIVE STRESS #VENOUS AIR INFUSION #NITRIC-OXIDE #VASCULAR-RESPONSES #L-ARGININE #HYPERTENSION #VASOCONSTRICTION #DOGS #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion